3rd post of this same article
>>>>> https://www.francesoir.fr/opinions-trib ... es-vaccins
Possibility of integrating RNA into DNA
All scientists agree that the long-term risks of this vaccine are not known. The biggest would be that this mRNA or DNA integrates into our genome and produces the spike protein. This kind of phenomenon, in addition to producing spike continuously, can also interfere at the genome level on tumor promoter genes and induce cancer. This is a possible and described phenomenon, carried out by enzymes of reverse transcriptase type (from RNA to DNA).
The possibility, and this would be the worst, that RNA integrates definitively into DNA (at least two enzymes in the human body are capable of doing this) (Zhang, L et al., 2021) (Chandramouly G et al. ., 2021). There, it would then be an outbreak of cancers that could be observed between one and ten years. Neurological and autoimmune diseases can also result (Seneff S and Nigh, 2021).
Note on adjuvants
Some of the nanolipids used by Pfizer or Moderna to encapsulate mRNA have never been used, either by injection or orally, not presented on the ECHA reference site (type ALC-1059 nanolipids) and including the by-products are known potential carcinogens (N, N-Dimethyltetradecylamine) (EMA, 2021).
There is also the presence of allergenic adjuvants, such as PEG which can lead to anaphylactic shock (Shiraishi K et al., 2019) (Kounis NG et al., 2021)
A point of concern, in addition to the toxicity of the spike, is that these naonolipids are also known to cause clotting problems. In fact, Moderna admits it, even if one reads the patent on the injection of mRNA vaccine encapsulated in nanolipids, which is the basis of the technique of current vaccines: WO 2017/099823 A1. COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS. June 15, 2017.
"In some embodiments, the adverse reaction includes coagulopathy, disseminated intravascular coagulation (DIC), vascular thrombosis, complement activation pseudo-allergy (CARPA), acute phase response (APR) , or a combination of these. »This patent even provides for the addition of anticoagulants, antiallergics! :
"In some embodiments, the agent (additive molecule) inhibits platelet activation. In some embodiments, the agent is an inhibitor of platelet aggregation. In some embodiments, the inhibitor of platelet aggregation is aspirin or clopidrogrel (PLAVIX®). In some embodiments, the platelet aggregation inhibitor is selected from aspirin / pravastatin, cilostazol, prasugrel, aspirin / dipyridamole, ticagrelor, cangrelor, elinogrel, dipyridamole, and ticlopidine . In some embodiments, the agent inhibits CD36 ”(MODERNA, 2017). "
We clearly note that the harmful effects of these nanolipids have a lot in common with those of COVID, including in their inflammatory mode of action (complement pathway) (Bumiller-Bini V et al., 2021)!
For all the reasons set out in this article and supported by the scientific literature, we see that the serious forms and deaths observed, in particular with mRNA and DNA type vaccines, which are called vaccines a little quickly, even s 'they do indeed produce antibodies directed against the SARS-CoV2 virus, can be explained by biological and biochemical mechanisms.
This toxicity, in particular due to the spike protein, has been known for more than ten years. Some of the adjuvants and the nanolipids surrounding the mRNA are also of concern and may participate in the serious side effects observed, including, in particular, thrombosis.
We do not have enough perspective on these gene technologies as the inventor himself, Robert Malone calls them . It would be wiser to recommend conventional vaccines (despite the risks of ADE as well) or with a deactivated spike protein and safer and known adjuvants. This could also encourage many citizens, enlightened or not, to be vaccinated.
We are therefore witnessing total blind experimentation on a planetary scale and this is unacceptable, because the risk is totally inconsiderate, particularly in view of the mortality and low lethality of this COVID disease. The lethality (mortality in people who contract the virus) is on average, in the world, between 0.5 and 1% against 0.1% for influenza (John Hopkins data, July 2021).
There is still time to face the real benefits and the real risks of this vaccination, and in particular among young people, when they are very little affected by the disease, and vaccines do not prevent contamination. Let us not lose sight of the fact that vaccination, apart from populations at risk, is aimed at healthy subjects, on whom ethics dictate that they do not run any risk , primum non nocere .
Angeli F, Spanevello A, Reboldi G, Visca D, Verdecchia P. SARS-CoV-2 vaccines: Lights and shadows. Eur J Intern Med. 2021 Jun; 88: 1-8.
Argenziano MG, Bruce SL, Slater CL, Tiao JR, Baldwin MR, Barr RG, et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. Bmj-British Medical Journal. 2020; 369.
Bahl, K., Senn, JJ, Yuzhakov, O., Bulychev, A., Brito, LA, Hassett, KJ ... Ciaramella, G. (2017). Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses. Molecular Therapy 25 (6): 1316-1327.
Bril F, Al Diffalha S, Dean M, Fettig DM. Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty? J Hepatol. 2021 Jul; 75 (1): 222-224.
Bumiller-Bini V, de Freitas Oliveira-Toré C, Carvalho TM, Kretzschmar GC, Gonçalves LB, Alencar NM, Gasparetto Filho MA, Beltrame MH, Winter Boldt AB. MASPs at the crossroad between the complement and the coagulation cascades - the case for COVID-19. Genet Mol Biol. 2021 Mar 17; 44 (1 Suppl 1): e20200199.
Buzhdygana, TP, DeOrec, BJ, Baldwin-Leclair, A., Bullock, TA, McGary, H. M, Ramirez, SH (2020). The SARS-CoV-2 Spike Protein Alters Barrier Function in 2D Static and 3D Microfluidic in-Vitro Models of the Human Blood-Brain Barrier. Neurobiology of Disease 146: 105131.
Cardozo T, Veazey R. Informed consent disclosure to vaccine trial subjects of risk of COVID-19 vaccines worsening clinical disease. Int J Clin Pract. 2021 Mar; 75 (3): e13795.
Chandramouly G, Zhao J, McDevitt S, Rusanov T, Hoang T, Borisonnik N, Treddinick T, Lopezcolorado FW, Kent T, Siddique LA, Mallon J, Huhn J, Shoda Z, Kashkina E, Brambati A, Stark JM, Chen XS , Pomerantz RT. Polθ reverse transcribes RNA and promotes RNA-templated DNA repair. Sci Adv. 2021 Jun 11; 7 (24): eabf1771.
Chen IY, Chang SC, Wu HY, Yu TC, Wei WC, Lin S, Chien CL, Chang MF. Upregulation of the chemokine (CC motif) ligand 2 via a severe acute respiratory syndrome coronavirus spike-ACE2 signaling pathway. J Virol. 2010 Aug; 84 (15): 7703-12.
Chu KH, Tsang WK, Tang CS, Lam MF, Lai FM, To KF, et al. Acute renal respiratory impairment in coronavirus associated severe acute syndrome. Kidney Int. 2005; 67 : 698–705.
by Melo LA, Almeida-Santos AF. Neuropsychiatric Properties of the ACE2 / Ang- (1-7) / Mas Pathway: A Brief Review. Protein Pept Lett. 2020; 27 (6): 476-483.
Diaz GA, Parsons GT, Gering SK, Meier AR, Hutchinson IV, Robicsek A. Myocarditis and Pericarditis After Vaccination for COVID-19. JAMA. 2021 Aug 4.
Dionne A, Sperotto F, Chamberlain S, et al. Association of Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children. JAMA Cardiol. Published online August 10, 2021.
EMA Public Assessment Report on Pfizer-BioNTech Vaccine. (2020). Accessed 5/2/21.
Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med. 2021 Jun 3; 384 (22): 2092-2101.
Hermans C, Goldman M. Thrombosis and vaccines: a new challenge in the COVID-19 pandemic. Louvain Med 2021 Apr: 140: 207-215.
John Hopkins data, July 2021 .
Huang C, Wang Y, Li X, RenL, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, The Lancet 395 (10223) ( 2020) 497–506.
Jaume M, Yip MS, Kam YW, Cheung CY, Kien F, Roberts A, et al. SARS CoV subunit vaccine: antibody-mediated neutralization and enhancement. Hong Kong Med J 2012; 18 (Suppl 2): 31–6.
Klempin F, Mosienko V, Matthes S, Villela DC, Todiras M, Penninger JM, Bader M, Santos RAS, Alenina N. Depletion of angiotensin-converting enzyme 2 reduces brain serotonin and impairs the running-induced neurogenic response. Cell Mol Life Sci. 2018 Oct; 75 (19): 3625-3634.
Konstantinidis I, Tsakiropoulou E, Hähner A, de With K, Poulas K, Hummel T. Olfactory dysfunction after coronavirus disease 2019 (COVID-19) vaccination. Int Forum Allergy Rhinol. 2021 May 28: 10.1002 / alr. 22809.
Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y, Yang P, Zhang Y, Deng W, Bao L, Zhang B, Liu G, Wang Z, Chappell M, Liu Y, Zheng D , Leibbrandt A, Wada T, Slutsky AS, Liu D, Qin C, Jiang C, Penninger JM. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005 Aug; 11 (8): 875-9.
Lee WS, Wheatley AK, Kent SJ, DeKosky BJ. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol. 2020 Oct; 5 (10): 1185-1191.
Lei Y, Zhang J, Schiavon CR, He M, Chen L, Shen H, Zhang Y, Yin Q, Cho Y, Andrade L, Shadel GS, Hepokoski M, Lei T, Wang H, Zhang J, Yuan JX, Malhotra A , Manor U, Wang S, Yuan ZY, Shyy JY. SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2. Circ Res. 2021 Apr 30; 128 (9): 1323-1326.
Lin L, Jiang X, Zhang Z, Huang S, Zhang Z, Fang Z, et al. Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. Gut. 2020; 69 : 997–1001.
Long B, Bridwell R, Gottlieb M. Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines. Am J Emerg Med. 2021 May 25; 49: 58-61.
Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA neurology. 2020: e201127
MODERNA, INC. WO 2017/099823 A1. COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS. June 15, 2017.
Nuovo GJ, Magro C, Shaffer T, Awad H, Suster D, Mikhail S, He B, Michaille JJ, Liechtenstein B, Tili E. Endothelial cell damage is the central part of COVID-19 and a mouse model induced by injection of the S1 subunit of the spike protein. Ann Diagn Pathol. 2021 Apr; 51: 151682.
Ogata AF, Cheng CA, Desjardins M, Senussi Y, Sherman AC, Powell M, Novack L, Von S, Li X, Baden LR, Walt DR. Circulating SARS-CoV-2 Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients. Clin Infect Dis. 2021 May 20: ciab465.
Patra T, Meyer K, Geerling L, Isbell TS, Hoft DF, Brien J, Pinto AK, Ray RB, Ray R. SARS-CoV-2 spike protein promotes IL-6 trans-signaling by activation of angiotensin II receptor signaling in epithelial cells. PLoS Pathog. 2020 Dec 7; 16 (12): e1009128.
Rela M, Jothimani D, Vij M, Rajakumar A, Rammohan A. Autoimmune hepatitis following COVID vaccination. J Autoimmun. 2021 Jul 3; 123: 102688.
Rhea EM, Logsdon AF, Hansen KM et al. The S1 Protein of SARS-CoV-2 Crosses the Blood-Brain Barrier in Mice. Nature Neuroscience 2021; 24: 368-378.
Rocco A, Sgamato C, Compare D, Nardone G. Autoimmune hepatitis following SARS-CoV-2 vaccine: May not be a casualty. J Hepatol. 2021 Jun 9: S0168-8278 (21) 00412-8.
Seneff S and Nigh G. Worse Than the Disease? Reviewing Some Possible Unintended Consequences of the mRNA Vaccines. International Journal of Vaccine Theory, Practice, and Research 2 (1), May 10, 2021 Page | 38
Shiraishi K, Yokoyama M. Toxicity and immunogenicity concerns related to PEGylated-micelle carrier systems: a review. Sci Technol Adv Mater. 2019 Apr 15; 20 (1): 324-336.
Starr TN, Greaney AJ, Hilton SK, Ellis D, Crawford KHD, Dingens AS, Navarro MJ, Bowen JE, Tortorici MA, Walls AC, King NP, Veesler D, Bloom JD. Deep Mutational Scanning of SARS-CoV-2
Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding. Cell. 2020 Sep 3; 182 (5): 1295-1310.e20.
Suzuki YJ, Gychka SG. SARS-CoV-2 Spike Protein Elicits Cell Signaling in Human Host Cells: Implications for Possible Consequences of COVID-19 Vaccines. Vaccines (Basel). 2021 Jan 11; 9 (1): 36.
Ulrich H, Pillat MM, Tárnok A. Dengue Fever, COVID-19 (SARS-CoV-2), and Antibody-Dependent Enhancement (ADE): A Perspective. Cytometry A. 2020 Jul; 97 (7): 662-667.
Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet 2021; 397 (10269): 99–111.
Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J Virol. 2020 Mar 17; 94 (7): e00127-20.
Weingartl H, Czub M, Czub S, Neufeld J, Marszal P, Gren J, Smith G, Jones S, Proulx R, Deschambault Y, Grudeski E, Andonov A, He R, Li Y, Copps J, Grolla A, Dick D , Berry J, Ganske S, Manning L, Cao J. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol. 2004 Nov; 78 (22): 12672-6.
Yahi N, Chahinian H, Fantini J. Infection-enhancing anti-SARS-CoV-2 antibodies recognize both the original Wuhan / D614G strain and Delta variants. A potential risk for mass vaccination? J Infect. 2021 Aug 9: S0163-4453 (21) 00392-3.
Yu J, Yuan X, Chen H, Chaturvedi S, Braunstein EM, Brodsky RA. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood. 2020 Oct 29; 136 (18): 2080-2089.
Zhang S, Liu Y, Wang X, Yang L, Li H, Wang Y, Liu M, Zhao X, Xie Y, Yang Y, Zhang S, Fan Z, Dong J, Yuan Z, Ding Z, Zhang Y, Hu L SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. J Hematol Oncol. 2020 Sep 4; 13 (1): 120.
Author (s): Dr Jean-François Lesgards, for FranceSoir